Pharmacological treatment of fibromyalgia

M. Di Franco, C. Iannuccelli, F. Atzeni, M. Cazzola, F. Salaffi, G. Valesini, P. Sarzi-Puttini

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Fibromyalgia (FM) is a common syndrome characterised by widespread pain and at least 11/18 painful tender points that requires multimodal pharmacological treatment also combined with non-pharmacological therapy. Various drugs currently are available to control the complex and different symptoms reported by patients. Only three drugs (duloxetine, milnacipram, pregabalin) are approved by the American Food and Drug Administration (FDA) and none by the European Medicines Agency (EMEA), consequently, offlabel use is habitual in Europe. Most of the drugs improve only one or two symptoms; no drug capable of overall symptom control is yet available. Furthermore, different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), opioids, non-steroidal antiinflammatory drugs (NSAIDs), growth hormone, corticosteroids and sedative hypnotics. As no single drug fully manages FM symptoms, multicomponent therapy should be used from the beginning. Various pharmacological treatments have been used to treat FM with inconclusive results, and gradually increasing low doses is suggested in order to maximise efficacy. The best treatment should be individualised and combined with patient education and non-pharmacological therapy.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume28
Issue number6 SUPPL. 63
Publication statusPublished - 2010

Fingerprint

Fibromyalgia
Pharmacology
Pharmaceutical Preparations
Therapeutics
Combined Modality Therapy
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Patient Education
United States Food and Drug Administration
Hypnotics and Sedatives
Opioid Analgesics
Growth Hormone
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Pain

Keywords

  • Drug
  • Fibromyalgia
  • Non-pharmacological therapy

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Di Franco, M., Iannuccelli, C., Atzeni, F., Cazzola, M., Salaffi, F., Valesini, G., & Sarzi-Puttini, P. (2010). Pharmacological treatment of fibromyalgia. Clinical and Experimental Rheumatology, 28(6 SUPPL. 63).

Pharmacological treatment of fibromyalgia. / Di Franco, M.; Iannuccelli, C.; Atzeni, F.; Cazzola, M.; Salaffi, F.; Valesini, G.; Sarzi-Puttini, P.

In: Clinical and Experimental Rheumatology, Vol. 28, No. 6 SUPPL. 63, 2010.

Research output: Contribution to journalArticle

Di Franco, M, Iannuccelli, C, Atzeni, F, Cazzola, M, Salaffi, F, Valesini, G & Sarzi-Puttini, P 2010, 'Pharmacological treatment of fibromyalgia', Clinical and Experimental Rheumatology, vol. 28, no. 6 SUPPL. 63.
Di Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G et al. Pharmacological treatment of fibromyalgia. Clinical and Experimental Rheumatology. 2010;28(6 SUPPL. 63).
Di Franco, M. ; Iannuccelli, C. ; Atzeni, F. ; Cazzola, M. ; Salaffi, F. ; Valesini, G. ; Sarzi-Puttini, P. / Pharmacological treatment of fibromyalgia. In: Clinical and Experimental Rheumatology. 2010 ; Vol. 28, No. 6 SUPPL. 63.
@article{7e13fed64b3e4bf6bc5adf4049b64e36,
title = "Pharmacological treatment of fibromyalgia",
abstract = "Fibromyalgia (FM) is a common syndrome characterised by widespread pain and at least 11/18 painful tender points that requires multimodal pharmacological treatment also combined with non-pharmacological therapy. Various drugs currently are available to control the complex and different symptoms reported by patients. Only three drugs (duloxetine, milnacipram, pregabalin) are approved by the American Food and Drug Administration (FDA) and none by the European Medicines Agency (EMEA), consequently, offlabel use is habitual in Europe. Most of the drugs improve only one or two symptoms; no drug capable of overall symptom control is yet available. Furthermore, different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), opioids, non-steroidal antiinflammatory drugs (NSAIDs), growth hormone, corticosteroids and sedative hypnotics. As no single drug fully manages FM symptoms, multicomponent therapy should be used from the beginning. Various pharmacological treatments have been used to treat FM with inconclusive results, and gradually increasing low doses is suggested in order to maximise efficacy. The best treatment should be individualised and combined with patient education and non-pharmacological therapy.",
keywords = "Drug, Fibromyalgia, Non-pharmacological therapy",
author = "{Di Franco}, M. and C. Iannuccelli and F. Atzeni and M. Cazzola and F. Salaffi and G. Valesini and P. Sarzi-Puttini",
year = "2010",
language = "English",
volume = "28",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6 SUPPL. 63",

}

TY - JOUR

T1 - Pharmacological treatment of fibromyalgia

AU - Di Franco, M.

AU - Iannuccelli, C.

AU - Atzeni, F.

AU - Cazzola, M.

AU - Salaffi, F.

AU - Valesini, G.

AU - Sarzi-Puttini, P.

PY - 2010

Y1 - 2010

N2 - Fibromyalgia (FM) is a common syndrome characterised by widespread pain and at least 11/18 painful tender points that requires multimodal pharmacological treatment also combined with non-pharmacological therapy. Various drugs currently are available to control the complex and different symptoms reported by patients. Only three drugs (duloxetine, milnacipram, pregabalin) are approved by the American Food and Drug Administration (FDA) and none by the European Medicines Agency (EMEA), consequently, offlabel use is habitual in Europe. Most of the drugs improve only one or two symptoms; no drug capable of overall symptom control is yet available. Furthermore, different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), opioids, non-steroidal antiinflammatory drugs (NSAIDs), growth hormone, corticosteroids and sedative hypnotics. As no single drug fully manages FM symptoms, multicomponent therapy should be used from the beginning. Various pharmacological treatments have been used to treat FM with inconclusive results, and gradually increasing low doses is suggested in order to maximise efficacy. The best treatment should be individualised and combined with patient education and non-pharmacological therapy.

AB - Fibromyalgia (FM) is a common syndrome characterised by widespread pain and at least 11/18 painful tender points that requires multimodal pharmacological treatment also combined with non-pharmacological therapy. Various drugs currently are available to control the complex and different symptoms reported by patients. Only three drugs (duloxetine, milnacipram, pregabalin) are approved by the American Food and Drug Administration (FDA) and none by the European Medicines Agency (EMEA), consequently, offlabel use is habitual in Europe. Most of the drugs improve only one or two symptoms; no drug capable of overall symptom control is yet available. Furthermore, different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), opioids, non-steroidal antiinflammatory drugs (NSAIDs), growth hormone, corticosteroids and sedative hypnotics. As no single drug fully manages FM symptoms, multicomponent therapy should be used from the beginning. Various pharmacological treatments have been used to treat FM with inconclusive results, and gradually increasing low doses is suggested in order to maximise efficacy. The best treatment should be individualised and combined with patient education and non-pharmacological therapy.

KW - Drug

KW - Fibromyalgia

KW - Non-pharmacological therapy

UR - http://www.scopus.com/inward/record.url?scp=79952658682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952658682&partnerID=8YFLogxK

M3 - Article

C2 - 21176430

AN - SCOPUS:79952658682

VL - 28

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6 SUPPL. 63

ER -